These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 25133458)

  • 1. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
    J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
    Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
    J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients.
    Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
    Curr Med Res Opin; 2013 Oct; 29(10):1253-61. PubMed ID: 23796193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR; Armstrong EP; Nolan PE; Malone DC
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
    Rognoni C; Marchetti M; Quaglini S; Liberato NL
    Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
    Canestaro WJ; Patrick AR; Avorn J; Ito K; Matlin OS; Brennan TA; Shrank WH; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):724-31. PubMed ID: 24221832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
    Wisløff T; Hagen G; Klemp M
    Pharmacoeconomics; 2014 Jun; 32(6):601-12. PubMed ID: 24715603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
    Desai NR; Krumme AA; Schneeweiss S; Shrank WH; Brill G; Pezalla EJ; Spettell CM; Brennan TA; Matlin OS; Avorn J; Choudhry NK
    Am J Med; 2014 Nov; 127(11):1075-1082.e1. PubMed ID: 24859719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.